AMLX News and Press, Amylyx Pharmaceuticals Inc. From 05/08/24

2024-05-08 12:34:51 ET Major earnings expected before the bell on Thursday include: Medical Properties Trust ( MPW ) Plug Power ( PLUG ) Roblox ( RBLX ) Viatris ( VTRS ) Warner Bros. Discovery ( WBD ) Read the full article on Seeking Alpha ...

2024-05-08 11:43:06 ET More on Amylyx Pharmaceuticals An ALS Drug Fails Again Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript Amylyx down 6% despite encouraging ph...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, and Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, will participate in the 2024 Bank of America Health Care Confe...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the f...

2024-04-10 11:04:01 ET More on Amylyx Pharmaceuticals An ALS Drug Fails Again Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript Amylyx pulls ALS therapy Relyvrio fro...

- I nterim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression - All eig...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 9, 2024) - Faruqi & Faruqi, LLP, a leading national se...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 8, 2024) - Faruqi & Faruqi, LLP, a leading national se...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS clinical trial and the Samuel E. Schechter Professor of Med...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 7, 2024) - Faruqi & Faruqi, LLP, a leading national se...